Ablynx extends agreement with Wyeth
As part of the collaboration Ablynx receives research funding and would be entitled to future milestone payments and royalties upon commercialisation.
Dr. Edwin Moses, CEO and Chairman of Ablynx, commented: "We are very pleased with the progress of our partnership with Wyeth, which has world class capabilities in the development and commercialisation of biologics. We look forward to continuing our collaboration for another year. This is an important partnership for Ablynx and we are delighted to continue our joint efforts to advance the TNF-alpha Nanobody®-based programme to the next stage."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.